Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

Launched by CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER) · Sep 27, 2023

Keywords

ClinConnect Summary

The SchizOMICS trial is a study looking at two different medications, aripiprazole and paliperidone, to see which one works better and is safer for individuals experiencing their first episode of psychosis, which can be a symptom of schizophrenia. This trial will involve 244 participants between the ages of 15 and 40 who have not received much treatment for their condition before. Researchers want to understand how effective these medications are over three months and if certain biological markers can help explain why some people do not respond to treatment or develop side effects after a year.

To participate in this trial, individuals must be living in the study area and have a diagnosis related to schizophrenia but cannot have a history of drug dependence or significant neurological issues. Participants can expect to be monitored closely while receiving one of the two medications and will contribute to important research that may improve treatment options for others in the future. This trial is not yet recruiting, but it aims to provide valuable insights into tailoring treatments for young people facing psychosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 15-40 years;
• • 2. living in the catchment area;
• • 3. experiencing a first episode of psychosis;
• • 4. no prior treatment with antipsychotic medication or, if previously treated, a total lifetime of adequate antipsychotic treatment of less than 6 weeks;
• • 5. Diagnostic and Statistical Manual of Mental Disorders fth Edition (DSM-5) criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder.
• Exclusion Criteria:
• • 1. meeting DSM-5 criteria for drug dependence;
• • 2. meeting DSM-IV criteria for mental retardation;
• • 3. having a history of neurological disease or head injury.